Tagged with European

Denmark Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent.   Genmab has…

Denmark Although Zealand Pharma has been around for 23 years, it has made rapid progress since French national Emmanuel Dulac took the helm as president and CEO in April 2019, with a first new drug application (NDA) and approval, a first in-licensing, and two acquisitions.   Dulac – a veteran of…

Denmark The BioInnovation Institute (BII) is an initiative from the Novo Nordisk Foundation which aims to support entrepreneurial researchers and early-stage life science start-ups with up to DKK 18 million in founder-friendly funding. CEO Jens Nielsen highlights some of the BII’s milestones and success stories since its formation and Denmark’s progress…

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

Denmark Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the swift progress that the Danish biotech has made in his two and a half years as CEO. Dulac also highlights…

Italy Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.   Strong Fundamentals The association’s latest reporting shows that there are 751 active biotech firms in Italy, with a turnover…

Germany The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new investment in a Vienna production facility; BioNTech’s plans to inaugurate an mRNA manufacturing network in Africa; and the termination of the GSK/Merck KGaA cancer drug partnership.   German drug giant…

Italy Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in which Italian biotechs truly excel globally.   Italy and its researchers have created a good environment for science. However, the…

Switzerland This piece forms part of InFocus Biotechs to Watch Switzerland 2021, a deep dive into the Swiss biotech ecosystem and fundamentals, featuring data sets, feature articles, and profiles of some of its most exciting companies. Download here.   2020 stands out as having been the best year yet for Swiss…

Italy An overview of Italy’s pharma, biotech and medtech sectors by number of companies, production value, R&D investment, and number of employees. Made with Visme Infographic Maker   The Italian companies involved in healthcare, split by specialisation, R&D spend, and turnover Made with Visme Infographic Maker   Italy’s regions and their…

Switzerland Dr Vincent Forster of Versantis, a Swiss biotech aiming to develop a new generation of liver disease therapeutics and diagnostics, introduces the company’s foundation story, proprietary technology, and future development goals.   As a start-up company, we try to work in a very lean and dynamic way with a small…

Switzerland Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique transcription factor targeting molecule potentially represents a breakthrough in cancer research, the ways in which the firm’s funding strategy has evolved, and how its future growth trajectory might look.…